| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000096938377 |
| Molecular Weight (Da) | 350 |
| SMILES | COCCCn1c2ccccc2c2cc(C(=O)N3CCCCC3)ccc21 |
| Molecular Formula | C22N2O2 |
| Action | Agonist |
| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000096938377 |
| Molecular Weight (Da) | 350 |
| SMILES | COCCCn1c2ccccc2c2cc(C(=O)N3CCCCC3)ccc21 |
| Molecular Formula | C22N2O2 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000096938377 |
| Molar Refractivity | 102.425 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 26 |
| LogP | 3.701 |
| Activity (Ki) in nM | 83.176 |
| Polar Surface Area (PSA) | 34.47 |
| Pharmacokinetic Properties | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000096938377 |
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Oatp2b1 inhibitor | - |
| Oatp1b1 inhibitor | + |
| Oatp1b3 inhibitor | + |
| Mate1 inhibitor | - |
| Oct2 inhibitor | + |
| Bsep inhibitor | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.95092839 |
| Pharmacokinetic Properties | |
|---|---|
| Number of aromatic heavy atoms | 13 |
| Fraction csp3 | 0.41 |
| Ilogp | 3.58 |
| Xlogp3 | 3.79 |
| Wlogp | 4.08 |
| Mlogp | 3.19 |
| Silicos-it log p | 4.11 |
| Consensus log p | 3.75 |
| Esol log s | -4.37 |
| Esol solubility (mg/ml) | 0.0148 |
| Esol solubility (mol/l) | 0.0000422 |
| Esol class | Moderately |
| Ali log s | -4.21 |
| Ali solubility (mg/ml) | 0.0217 |
| Ali solubility (mol/l) | 0.000062 |
| Ali class | Moderately |
| Silicos-it logsw | -6.11 |
| Silicos-it solubility (mg/ml) | 0.000273 |
| Silicos-it solubility (mol/l) | 0.00000077 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.75 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 2.24 |
| Pharmacokinetic Properties | |
|---|---|
| Logs | -4.971 |
| Logd | 3.126 |
| Logp | 3.811 |
| F (20%) | 0.061 |
| F (30%) | 0.015 |
| Mdck | 1.92E-05 |
| Ppb | 0.9265 |
| Vdss | 1.398 |
| Fu | 0.0331 |
| Cyp1a2-inh | 0.863 |
| Cyp1a2-sub | 0.875 |
| Cyp2c19-inh | 0.802 |
| Cyp2c19-sub | 0.105 |
| Cl | 4.263 |
| T12 | 0.077 |
| H-ht | 0.803 |
| Dili | 0.77 |
| Roa | 0.439 |
| Fdamdd | 0.773 |
| Skinsen | 0.32 |
| Ec | 0.003 |
| Ei | 0.056 |
| Respiratory | 0.807 |
| Bcf | 1.438 |
| Igc50 | 4.469 |
| Lc50 | 4.913 |
| Lc50dm | 4.984 |
| Nr-ar | 0.105 |
| Nr-ar-lbd | 0.005 |
| Nr-ahr | 0.564 |
| Nr-aromatase | 0.858 |
| Nr-er | 0.25 |
| Nr-er-lbd | 0.017 |
| Nr-ppar-gamma | 0.005 |
| Sr-are | 0.588 |
| Sr-atad5 | 0.029 |
| Sr-hse | 0.247 |
| Sr-mmp | 0.368 |
| Sr-p53 | 0.584 |
| Vol | 375.961 |
| Dense | 0.931 |
| Flex | 0.273 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 3 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 2 |
| Qed | 0.637 |
| Synth | 2.005 |
| Fsp3 | 0.409 |
| Mce-18 | 46.452 |
| Natural product-likeness | -1.174 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Accepted |
| Goldentriangle | Accepted |